MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 MapLight Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update Planning underway for ZEPHYR-2, the confirmatory Phase 3 trial of ML-007C-MA in schizophrenia, with topline results expected in the second half 2027 Enrollment ongoing in

Event · Earnings
Original reporting
Published Nov 16, 2026, 12:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 12:22 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$MPLT
Neutral
high confidence
Mentioned
$MPLT
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$MPLTNeutralHigh
01

Why it matters

The 8‑K provides the first detailed financial snapshot and trial timeline updates, essential for valuation models.

02

Market read

First‑hand financial and pipeline data for a micro‑cap biotech, likely to move the stock on cash‑runway and upcoming trial readouts.

03

What to watch

Potential dilution from future financing rounds if trial data disappoint, and competition from other CNS agents.

Relevance 7/10Novelty 8/10Timing: post‑market today
AlphAI · Earnings readMPLT · Q3 2026 · ended 2026-09-30

MapLight reports Q3 2026 net loss of $51.6 million, with $463.4 million in cash and ZEPHYR-2 Phase 3 planning underway

→Mixed quarter

The filing reports no revenue. Operating expenses rose sharply versus Q3 2025 (total operating expenses $55,343 thousand versus $31,498 thousand), and the company points to positive Phase 2 data and a runway through 2028. Two trial timelines appear inconsistently within the filing, and the company gives no numeric guidance.

EPS · GAAP
$(0.97)

Key metrics

shortened, hover for the filing’s print
MetricValueq/qy/y
Research and development expenses (Q3 2026)GAAP$44.21M––
General and administrative expenses (Q3 2026)GAAP$11.13M––
Total operating expenses (Q3 2026)GAAP$55.34M––
Loss from operations (Q3 2026)GAAP−$55.34M––
Interest income (Q3 2026)GAAP$3.09M––
Other income, net (Q3 2026)GAAP$633K––
Net loss (Q3 2026)GAAP−$51.62M––
Net loss per share, basic and diluted (Q3 2026)GAAP$(0.97)––
Research and development expenses (nine months ended Sep 30, 2026)GAAP$151.3M––
General and administrative expenses (nine months ended Sep 30, 2026)GAAP$32.07M––
Total operating expenses (nine months ended Sep 30, 2026)GAAP$183.4M––
Loss from operations (nine months ended Sep 30, 2026)GAAP−$183.4M––
Interest income (nine months ended Sep 30, 2026)GAAP$7.92M––
Other income, net (nine months ended Sep 30, 2026)GAAP$3.00M––
Net loss (nine months ended Sep 30, 2026)GAAP−$172.5M––
Net loss per share, basic and diluted (nine months ended Sep 30, 2026)GAAP$(3.60)––
Cash, cash equivalents and investments (as of Sep 30, 2026)other$463.4M––

Capital returns

  • No share repurchases or dividends are reported in the filing.
  • The company completed a $150 million private placement in August 2026 with new and existing institutional investors, as previously announced. The company says proceeds are expected to primarily support ML-007C-MA, including the planned ZEPHYR-2 trial and the ongoing VISTA trial, as well as working capital and other general corporate purposes.

What drove it

  • The company attributes the R&D increase to the ongoing advancement of its product candidates and to higher employee-related expenses, including an increase in stock-based compensation expense of $5.8 million.
  • The company attributes the G&A increase to higher employee-related expenses, including an increase in stock-based compensation expense of $4.3 million, and to increases in professional fees and other expenses.
  • The company states it is pausing significant further investment in preclinical and discovery-stage programs beyond near-term milestones and foregoing their advancement into clinical development under the current operating plan.
  • Interest income rose from $1,549 thousand to $3,094 thousand in Q3 2026. The filing does not give a cause for this change.

Concerns

  • Net loss was $51,616 thousand in Q3 2026 against $29,418 thousand in Q3 2025, and $172,476 thousand for the nine months against $81,604 thousand. The filing reports no revenue line.
  • Total operating expenses for the nine months were $183,395 thousand against $85,706 thousand a year earlier. R&D alone was $151,328 thousand against $73,726 thousand.
  • Timelines are inconsistent within the filing. The headline states ZEPHYR-2 topline results are expected in the second half 2027, while the business update states topline results are expected in 2028. The headline states VISTA topline results are now expected in 2028, while the business update states they are expected in the second half of 2027. The filing does not reconcile these statements.
  • The filing describes VISTA topline timing as 'now expected' in 2028 but does not explain the reason for the change.
  • The ML-004 program has no set path. The company plans an End-of-Phase 2 meeting with the FDA, then intends to evaluate development options, including potential strategic collaborations and/or funding alternatives.
  • The weighted-average share count is printed as 53,100,322 for Q3 2026 against 791,127 for Q3 2025, and per-share losses are printed as $(0.97) against $(37.18). The filing does not explain these share figures.
  • Stockholders' equity fell from $458,372 thousand to $445,771 thousand between December 31, 2025 and September 30, 2026, while the filing reports a net loss of $172,476 thousand for the nine months.

What to watch

  • The FDA End-of-Phase 2 meeting for ML-007C-MA, and the registrational path it sets for ZEPHYR-2.
  • The VISTA topline timing, given the conflicting dates in the filing (second half 2027 in the business update, 2028 in the headline).
  • The outcome of the planned End-of-Phase 2 meeting for ML-004 and any strategic collaboration or funding alternatives the company pursues.
  • Quarterly operating expense trend, particularly R&D and G&A, against the $463.4 million cash balance and the company's statement that cash funds the program through 2028.
  • Whether the company provides cash flow figures or updated cash runway detail in its Form 10-Q, which the filing references for the quarter ended September 30, 2026.

Balance sheet and cash flow

  • Cash, cash equivalents and investments: $463,413 thousand as of September 30, 2026, compared with $453,096 thousand as of December 31, 2025.
  • Total assets: $477,183 thousand as of September 30, 2026, compared with $479,512 thousand as of December 31, 2025.
  • Total current liabilities: $30,902 thousand as of September 30, 2026, compared with $16,229 thousand as of December 31, 2025.
  • Total liabilities: $31,412 thousand as of September 30, 2026, compared with $21,140 thousand as of December 31, 2025.
  • Total stockholders' equity: $445,771 thousand as of September 30, 2026, compared with $458,372 thousand as of December 31, 2025.
  • The company expects existing cash, cash equivalents and investments to be sufficient to fund the continued advancement of ML-007C-MA through 2028, based on current operational plans and assumptions.
  • The filing does not report operating cash flow, investing cash flow, free cash flow or debt.

Analysis

MapLight reported a third quarter 2026 net loss of $(51,616) thousand, or $(0.97) per share, against a net loss of $(29,418) thousand, or $(37.18) per share, in the third quarter of 2025. Total operating expenses rose to $55,343 thousand from $31,498 thousand, led by R&D at $44,208 thousand against $27,094 thousand and G&A at $11,135 thousand against $4,404 thousand. The company attributes both increases in part to higher stock-based compensation, citing $5.8 million for R&D and $4.3 million for G&A. Interest income was $3,094 thousand against $1,549 thousand. The filing reports no revenue. The filing does not print prior-quarter (Q2 2026) figures, so this read compares only with the prior-year quarter.

For the nine months ended September 30, 2026, R&D was $151,328 thousand against $73,726 thousand and total operating expenses were $183,395 thousand against $85,706 thousand. The nine-month net loss was $(172,476) thousand against $(81,604) thousand. Expense growth is therefore concentrated in clinical development and in employee-related costs, as the company itself describes them.

The pipeline narrative centers on ML-007C-MA. The company reports a Phase 2 ZEPHYR trial in schizophrenia that met its primary endpoint, and it has started start-up activities for ZEPHYR-2, a planned Phase 3 trial, with an End-of-Phase 2 FDA meeting planned. The Alzheimer's disease psychosis program has Fast Track designation and an ongoing Phase 2 VISTA trial of approximately 300 participants. For ML-004 in autism, the company plans an End-of-Phase 2 meeting, after which it will evaluate options including collaborations and funding alternatives. The company also states it is pausing significant further investment in preclinical and discovery-stage programs beyond near-term milestones.

The balance sheet shows cash, cash equivalents and investments of $463,413 thousand at September 30, 2026, against $453,096 thousand at December 31, 2025. Total stockholders' equity fell to $445,771 thousand from $458,372 thousand over the same period. The company cites an August 2026 $150 million private placement and says the cash position is expected to fund ML-007C-MA through 2028. The filing does not report operating cash flow, so the cash consumption rate cannot be read from it directly.

Trial timing is stated inconsistently: the headline gives 2027 for ZEPHYR-2 and 2028 for VISTA, while the body gives 2028 for ZEPHYR-2 and second half 2027 for VISTA. Readers should confirm these dates with the company before relying on them.

Management, verbatim

We believe that the strength and consistency of the ZEPHYR efficacy results, combined with the ease-of-use tolerability profile, provide a solid foundation for our planned Phase 3 trial and reinforce our confidence in the potential of ML-007C-MA in schizophrenia.

Chris Kroeger, Co-Founder and Chief Executive Officer

With our cash position expected to fund operations through 2028, we are well-positioned to advance both programs while maintaining strategic and financial flexibility.

Chris Kroeger, Co-Founder and Chief Executive Officer

Not in the filing

stated, not guessed
  • Prior-quarter (Q2 2026) figures for all income statement lines, because the filing prints only Q3 2026 and Q3 2025 for the quarter.
  • Year-over-year percentage changes for R&D, G&A, total operating expenses, net loss and EPS. The filing prints dollar amounts but no percentages.
  • Revenue, cost of sales and gross margin. The filing reports no revenue.
  • Operating cash flow, investing cash flow, free cash flow and cash burn for the quarter and nine months.
  • Prior-year cash balance at September 30, 2025, and a cash balance at June 30, 2026.
  • Net proceeds from the August 2026 private placement and the exact cash position after it.
  • Any numeric financial guidance, including operating expense or cash runway guidance beyond the statement that cash funds operations through 2028.
  • The reason for the change in VISTA topline timing to 2028, as stated in the headline.
  • The explanation for the difference between the ZEPHYR-2 and VISTA timing dates in the headline and the body of the filing.
  • Explanation of the change in weighted-average share count and per-share loss between periods.
  • Consensus estimates and share-price reaction, which are not part of this filing.
  • The previous outlook covered the period through the end of 2028 and non-numeric milestones only, which are not for the quarter reported here, so there is nothing to compare.

Written by an AI language model from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure is checked against the filing text, and a metric the filing does not print, or whose value, prior period and change do not add up, is dropped from the metrics. Guided figures in the outlook comparison come from the company’s previous release. The model can still misread a table, in the metrics or in the text, so check a number in the filing before you rely on it. Consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.

Background

MapLight Therapeutics is a clinical‑stage biotech focused on CNS disorders, recently completed a $150M private placement.

Company-level read

Ticker impact

$MPLTNeutralHigh confidence
Context

SEC 8‑K filing reports Q3 2026 results, cash runway of $463.4M and upcoming Phase 3 trial timelines for ML‑007C‑MA.

Expected impact

potential modest upside as investors price in extended cash runway and upcoming data readouts

Evidence & confidence

The filing is the first public disclosure of the cash balance and detailed expense figures, providing fresh material for valuation and risk assessment.

Market effects

Highlights continued investment in CNS biotech pipelines, may boost peer sentiment in neuro‑psychiatric drug space.

Limited to US‑listed biotech investors; no broader regional effect.

Modest, as trial data could influence global CNS therapeutic outlook.

Counterpoint

The sizable net loss and reliance on a single lead candidate could outweigh cash runway benefits, prompting short‑bias.

Key entities

  • MapLight Therapeutics

    Clinical‑stage biopharma developing ML‑007C‑MA for schizophrenia and Alzheimer’s disease psychosis.

  • Chris Kroeger

    Co‑Founder and CEO of MapLight Therapeutics.

Every MPLT earnings report

This story covers one filing. The ticker page keeps them all: each quarter's reported metrics with year-over-year and sequential comparisons, segments, guidance, and how the numbers landed against the company's own prior outlook.

Related articles

$MPLTMed

MapLight Therapeutics 3Q 2026: EPS ($0.97) — 10-Q Summary

MapLight Therapeutics reported a wider net loss of $51.62M in 3Q 2026, up 75.5% YoY, due to increased R&D and clinical trial expenses. Diluted EPS was ($0.97). The company plans a Phase 3 schizophrenia trial and expects Alzheimer’s disease psychosis trial results in 2H 2027. Cash reserves of $463.4M are expected to last through 2028.

$MPLTMed

MapLight Therapeutics, Inc. (MPLT): Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3…

MapLight Therapeutics, Inc. (MPLT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Reported positive results from the potentially registrational Phase 2 ZEPHYR trial of ML-007C-MA in schizophrenia, supporting advancement into a Phase 3 ZEPHYR-2 trial Continued advancement of ML-007C-MA in ADP, with enrollment ongoing in the Phase 2 VISTA trial and